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VASc score is identiﬁed in most pts who present with stroke. The
implication of this data is that such patients remain at risk for stroke,
and raise questions about current therapeutic strategies.
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BACKGROUND The research is dedicated to the possibility of treat-
ment of patients with ischemic stroke by means of transcatheter
intracerebral surgery.
METHODS The research involved 746 patients aged 29-81 (mean age
74), predominantly with intracerebral atherosclerosis, after ischemic
stroke: males - 552 (73.99%), females - 194 (26.01%). The evaluation of
CDR, MMSE, IB was conducted; cerebral CT, MRI, MRA, scintigraphy
(SG), rheoencephalography (REG), cerebral MUGA: macrofocal strokes
were detected in 126 (16.89%) patients; midfocal strokes were detec-
ted in 362 (48.53%) patients; microfocal strokes were found in 258
(34.58%) patients. Transcatheter interventions were conducted in 452
(60.59%) patients – test group. To perform transcatheter revasculari-
zation of main intracerebral arteries, high-energy pulsed lasers were
used, for revascularization of distal intracerebral branches - contin-
uous low-energy lasers. Conservative treatment including desa-
gregate, anticoagulant, vasodilatory, antioxidant and nootropic
therapy was conducted in 294 (39.41%) patients - control group.
RESULTS Test Group. After the intervention, a good immediate
outcome was achieved in 443 (98.01%) patients due to the restoration
of patency and lumen of the affected vessels, as well as to the
collateral revascularization. 12 months after the treatment, the results
depended on the size of the ischemic lesion and the timing of the
intervention. Good clinical outcome (complete recovery of mental and
motor functions - IB 90-100) was obtained in 162 (35.84%) patients;
Satisfactory clinical outcome (incomplete recovery of mental and
motor functions - IB 75-85) - 212 (46.90%) patients; Relatively satis-
factory clinical outcome (partial restoration of mental and motor
functions - IB 60-70) - 78 (17.26%) patients; Relatively positive clinical
outcome (absence of negative dynamics with insigniﬁcant reduction
of mental and motor functions - IB below 60) was not obtained in any
case. Control Group. good clinical outcome was not obtained in any
case; satisfactory clinical outcome was obtained in 44 (14.97%) pa-
tients; relatively satisfactory clinical outcome - in 91 (30.95%) pa-
tients; relatively positive clinical outcome - in 159 (54.08%) patients.
CONCLUSIONS Transcatheter laser revascularization in the treatment
of ischemic stroke with intracerebral atherosclerotic lesions is more
effective than therapies. Restoration of intracerebral blood ﬂow can
signiﬁcantly reduce the level of mental, cognitive, motor disorders
and return patients to their active daily life.
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BACKGROUND Embolic protection in Carotid Artery Stenting (CAS)
has been shown to reduce the rate of major adverse cardiac and ce-
rebrovascular events (MACCE). We present the results of the WISEclinical study performed in high surgical risk patients using the novel
WIRION Embolic Protection System (EPS).
METHODS The WISE clinical study is a a multi-center, single arm
study performed on high surgical risk patients undergoing CAS using
the WIRION EPS. The primary safety endpoint was a composite of
Major Adverse Cardiac and Cerebrovascular Events (MACCE),
including Death, Stroke, and Myocardial Infarction (DSMI) occurring
within 30 days post-procedure. The primary end point was compared
to historical control from 5 previous US studies. WIRION is a distal EPS
that includes a rapid exchange, pre-crimped ﬁlter that can be used
with any commercially available 0.014” guide wire. The WIRION
remotely activated locking mechanism allows the stand-alone ﬁlter
unit to be positioned at any location on the wire along the vessel
without compromising wire performance. The WIRION Retrieval
Catheter includes a retractable tip allows smooth passage through the
stented area, minimize the risk of entanglement with the stent struts.
RESULTS One hundred and twenty (n¼120) high surgical risk patients,
mean age of 73.9 years were enrolled in the study. The treated lesions
average stenosis rate was 84% and 88% of the patients were asymp-
tomatic. WISE study primary endpoint was met at interim, following
recruitment of 120 out of the planned 240 patients. The 30-day com-
posite primary endpoint of MACCE as adjudicated by the CEC, was 3.3%
with 0% death. The obtained P value was 0.0008, less than the 0.0015
which is the performance goal of the study thus theWIRION systemmet
the primary end point. In 2 out of the 4 patients undergo MACCE the
event was non procedure nor device related. The following table pre-
sents the WISE primary endpoint results versus the historical control
data. The device success rate was 99.2% (119/120 patients) and angio-
graphic success was achieved in 97.5% (117 patients).Historical Control Group [%]Study Group
[%]ARCHeR 2 ARCHeR 3 BEACH MAVERIC CREATE AVG WISEAny MACCE 8.6 8.3 5.4 5.4 6.2 6.3 3.3Death 2.2 1.4 1.6 1 1.9 1.6 0Stroke 5.4 5.5 4.5 4.2 4.5 4.6 2.5Major 1.1 1.4 1.1 2.6 3.3 2.1 0Minor 4 3.5 2.2 1.2 0.5 1.9 1.6Myocardial Infraction 2.9 1.4 1.1 1.4 1 1.5 0.8EPS Accunet FilterWire GuardWire
(Medtronic)Spider WIRION(Abbott) (Boston Sci.) (ev3) (Gardia)CONCLUSIONS WISE study met its primary endpoint at interim,
demonstrating the safety and effectiveness of WIRION EPS in CAS of
high surgical risk patients when compared to the historical data of 4
other US marketed EPSs. It is simple to use and is highly rated by its
multiple users. The ability to cross the lesion over a guide wire of
choice and deploy the ﬁlter at the exact desired location creates a
unique, natural and appealing advantage for all indications.
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BACKGROUND New oral anticoagulants and the Watchman device
both represent alternatives to warfarin for stroke prophylaxis for atrial
ﬁbrillation. However, there are no studies comparing these new
treatment approaches. Thus, we performed a network meta-analysis
to indirectly compare Watchman and new oral anticoagulants (NOAC)
among atrial ﬁbrillation patients.
METHODS We performed a MEDLINE search for studies comparing
between warfarin and NOAC (dabigatran, rivaroxaban, apixaban and
edoxaban) or Watchman device in patients with atrial ﬁbrillation that
reported clinical outcomes. Mixed treatment comparison model gen-
eration was performed to directly and indirectly compare between
NOAC, warfarin and Watchman.
RESULTS A total of 14 studies with 246,005 patients were included in
the analysis, among which 122,811 were treated with warfarin, 119,602
were treated with NOAC and 732 had a Watchman device implanted.
